ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Tocilizumab"

  • Abstract Number: 2668 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial

    Navita Malallieu1, Min Bao 2 and John Stone 3, 1Roche Innovation Center, New York, NY, 2Genentech, South San Francisco, CA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Tocilizumab (TCZ) administered subcutaneously weekly or every 2 weeks with a 26-week prednisone taper (TCZ-QW or TCZ-Q2W) was superior to placebo given with a…
  • Abstract Number: 313 • 2019 ACR/ARP Annual Meeting

    Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

    William Torelli1, James Ross 2, Thomas Quinn 2, Kourtney Erickson 1, Andrea Soliman 1 and Attiya Harit 3, 1Lehigh Valley Health Network, Allentown, PA, 2lehigh valley health network, allentown, 3lehigh valley health organization, allentown

    Background/Purpose: Background/Purpose: Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Tocilizumab and sarilumab…
  • Abstract Number: 2680 • 2019 ACR/ARP Annual Meeting

    Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients

    Mónica Calderón-Goercke1, Javier Loricera 2, DIANA PRIETO- PENA 3, Santos Castañeda 4, Vicente Aldasoro Caceres 5, Ignacio Villa 6, Alicia Humbría 7, Clara Moriano 8, Susana Romero-Yuste 9, Javier Narváez 10, Catalina Gómez-Arango 11, Eva Perez Pampín 12, Rafael Melero 13, Elena Becerra-Fernández 14, Marcelino Revenga 15, Noelia Álvarez-Rivas 16, Carles Galisteo 17, Francisca Sivera 18, Alejandro Olivé-Marqués 19, María Álvarez del buergo 20, Luisa Marena-Rojas 21, Carlos Fernández-López 22, Francisco Navarro 23, E. Raya 24, Eva Galindez-Agirregoikoa 25, Beatriz Arca 26, Roser Solans-Laqué 27, Arantxa Conesa 28, Cristina Hidalgo 29, Carlos Vazquez 30, Jose Andrés Román-Ivorra 31, Pau Lluch 32, Sara Manrique 33, P. Vela 34, Eugenio de Miguel 35, Carmen Torres-Martín 36, Juan Carlos Nieto 37, Carmen Ordas-Calvo 38, Eva salgado-Pérez 39, Cristina Luna-Gómez 40, F. Javier Toyos-Sáenz De Miera 41, Nagore Fernández-Llanio 42, Antonio García 43, Carmen Larena 44, María Varela-García 5, Elena Aurrecoechea 6, Francisco Ortiz-Sanjuán 31, Jose Luis Hernández 1, Miguel Angel González-Gay 45 and Ricardo Blanco 46, 1Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, 5Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, 6Hospital de Sierrallana, Torrelavega, Cantabria, Spain, 7Hospital de La Princesa, Madrid, Madrid, Spain, 8Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, 9Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, 10Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, 11Hospital Alto Deba, Mondragon, Pais Vasco, Spain, 12Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 13Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 14Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, 15Hospital Ramón y Cajal, Madrid, Madrid, Spain, 16Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 17Hospital Parc Taulí, Barcelona, Catalonia, Spain, 18Hospital General Universitario de Elda, Elda, Spain, 19Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, 20Hospital Río Carrión, Palencia, Castilla y Leon, Spain, 21Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, 22Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 23Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, 24Hospital San Cecilio, Granada, Andalucia, Spain, 25Hospital de Basurto, Bilbao, Pais Vasco, Spain, 26Hospital Universitario San Agustín, Avilés, Asturias, Spain, 27Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, 28Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, 29Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 30Hospital Miguel Servet, Zaragoza, Aragon, Spain, 31Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, 32Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, 33Hospital Regional de Málaga, Málaga, Andalucia, Spain, 34Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, 35Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 36Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, 37Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, 38Hospital Cabueñes, Gijón, Asturias, Spain, 39Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, 40Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, 41Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, 42Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, 43Hospital Virgen de las Nieves, Granada, Andalucia, Spain, 44Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 45Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 46Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) is the only biological agent approved in Giant Cell Arteritis (GCA). There is general agreement on the initial and the standard maintenance…
  • Abstract Number: 1244 • 2019 ACR/ARP Annual Meeting

    Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children

    Jasmin B. Kuemmerle-Deschner1, Daniel Sturm 1 and Susanne Benseler 2, 1University Hospital Tuebingen, Tuebingen, Germany, 2Alberta Children’s Hospital Research Institute, Calgary, Canada

    Background/Purpose: Evidence based treatment options for children and adults with unclassified autoinflammatory diseases (AID) are limited. Frequently, IL-1-inhibition is primarily tried to control the severe…
  • Abstract Number: 2682 • 2019 ACR/ARP Annual Meeting

    Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution

    Mónica Calderón-Goercke1, Javier Loricera 2, DIANA PRIETO- PENA 3, Santos Castañeda 4, Vicente Aldasoro Caceres 5, Ignacio Villa 6, Alicia Humbría 7, Clara Moriano 8, Susana Romero-Yuste 9, Javier Narváez 10, Catalina Gómez-Arango 11, Eva Perez Pampín 12, Rafael Melero 13, Elena Becerra-Fernández 14, Marcelino Revenga 15, Noelia Álvarez-Rivas 16, Carles Galisteo 17, Francisca Sivera 18, Alejandro Olivé-Marqués 19, María Álvarez del buergo 20, Luisa Marena-Rojas 21, Carlos Fernández-López 22, Francisco Navarro 23, E. Raya 24, Eva Galindez-Agirregoikoa 25, Beatriz Arca 26, Roser Solans-Laqué 27, Arantxa Conesa 28, Cristina Hidalgo 29, Carlos Vazquez 30, Jose Andrés Román-Ivorra 31, Pau Lluch 32, Sara Manrique 33, P. Vela 34, Eugenio de Miguel 35, Carmen Torres-Martín 36, Juan Carlos Nieto 37, Carmen Ordas-Calvo 38, Eva salgado-Pérez 39, Cristina Luna-Gómez 40, F. Javier Toyos-Sáenz De Miera 41, Nagore Fernández-Llanio 42, Antonio García 43, Carmen Larena 44, Elena Aurrecoechea 6, Francisco Ortiz-Sanjuán 31, Montserrat Corteguera 36, Jose Luis Hernández 1, Miguel Angel González-Gay 45 and Ricardo Blanco 46, 1Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, 5Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, 6Hospital de Sierrallana, Torrelavega, Cantabria, Spain, 7Hospital de La Princesa, Madrid, Madrid, Spain, 8Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, 9Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, 10Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, 11Hospital Alto Deba, Mondragon, Pais Vasco, Spain, 12Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 13Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 14Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, 15Hospital Ramón y Cajal, Madrid, Madrid, Spain, 16Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 17Hospital Parc Taulí, Barcelona, Catalonia, Spain, 18Hospital General Universitario de Elda, Elda, Spain, 19Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, 20Hospital Río Carrión, Palencia, Castilla y Leon, Spain, 21Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, 22Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 23Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, 24Hospital San Cecilio, Granada, Andalucia, Spain, 25Hospital de Basurto, Bilbao, Pais Vasco, Spain, 26Hospital Universitario San Agustín, Avilés, Asturias, Spain, 27Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, 28Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, 29Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 30Hospital Miguel Servet, Zaragoza, Aragon, Spain, 31Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, 32Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, 33Hospital Regional de Málaga, Málaga, Andalucia, Spain, 34Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, 35Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 36Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, 37Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, 38Hospital Cabueñes, Gijón, Asturias, Spain, 39Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, 40Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, 41Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, 42Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, 43Hospital Virgen de las Nieves, Granada, Andalucia, Spain, 44Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 45Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 46Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) has proved to be effective in the management of Giant Cell Arteritis (GCA). Based on results of the GiACTA trial, it has…
  • Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting

    Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study

    Martin Michaud1, Thomas Sene 2, Pascal Chazerain 2, Geoffrey Urbanski 3, Frederique Retornaz 4, Boris Bienvenu 5, Laurent Chiche 4, Florian Catros 6, Laurent Sailler 7, Laurent Alric 8, Jean Thomas Giraud 9, Léo Caudrelier 10, Slim Lassoued 10, Sophie Ancellin 6, Olivier Lidove 2 and Francis Gaches 6, 1Joseph Ducuing Hospital, Toulouse, France, 2Hôpital Croix Saint Simon, Paris, France, 3CHU Angers, Angers, France, 4Hôpital Européen, Marseille, France, 5Hôpital Saint Joseph, Marseille, France, 6Hôpital Joseph Ducuing, Toulouse, France, 7University Hospital of Toulouse, Toulouse, France, 8CHU Toulouse, Toulouse, France, 9Hôpital de Tarbes, Tarbes, France, 10Hôpital de Cahors, Cahors, France

    Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
  • Abstract Number: 2770 • 2019 ACR/ARP Annual Meeting

    Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission

    Joanna Kedra1, Philippe Dieudé 2, Hubert Marotte 3, Alexandre Lafourcade 4, Emilie Ducourau 5, Thierry Schaeverbeke 6, Aleth Perdriger 7, Martin SOUBRIER 8, Jacques Morel 9, Arnaud Constantin 10, Emmanuelle Dernis 11, Valérie Royant 12, Jean-Hugues Salmon 13, Thao Pham 14, Jacques-Eric Gottenberg 15, Edouard Pertuiset 16, Maxime Dougados 17, Valérie Devauchelle Pensec 18, Philippe Gaudin 19, gregoire Cormier 20, Philippe Goupille 21, Xavier Mariette 22, Francis Berenbaum 23, Didier Alcaix 24, Sid-Ahmed Rouidi 25, Jean-Marie Berthelot 26, Agnès Monnier 27, Christine Piroth 28, Frédéric Lioté 29, Vincent Goeb 30, Cécile Gaujoux-Viala 31, Isabelle Chary-Valckenaere 32, David Hajage 4, Florence Tubach 33 and Bruno Fautrel 34, 1Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, 2Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, 3University Hospital, St Etienne, France, 4Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 5Rheumatology Department, CHR Orléans, Orléans, France, 6FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, 7Rheumatology department, Rennes University Hospital, France, Rennes, France, 8CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, 9CHU MONTPELLIER, MONTPELLIER, France, 10Hôpital Pierre-Paul Riquet, Toulouse, France, 11Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 12Rheumatology Department, Chartres Hospital, Chartres, France, 13Rheumatology, Reims University Hospital, Reims, Reims, France, 14Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 15Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 16Rheumatology Department, Pontoise Hospital, Pontoise, France, Pontoise, France, 17Cochin Hospital, Paris, France, 18University Hospital of Brest, Brest, France, 19Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 20CHD Vendée, La Roche sur Yon, France, 21Tours University-Hospital, Tours, France, Tours, France, 22Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 23Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France, 24Rheumatology Department, Le Havre Hospital, Le Havre, 25Rheumatology Department, Dreux, France, 26University Hospital, Nantes, France, 27Internal Medicine Department, CH Côte Basque, Bayonne, France, 28Rheumatology Department, Dijon Hospital, Dijon, France, 29Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France, 30Rheumatology Department, Amiens University Hospital, Amiens, France, 31Nîmes University Hospital, Nîmes, France, 32Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 33Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 34Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARD) tapering is proposed by clinical practice guidelines in rheumatoid arthritis (RA) patients in sustained remission. However, no randomized…
  • Abstract Number: 1344 • 2019 ACR/ARP Annual Meeting

    Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study

    Eric Toussirot1, Hubert Marotte 2, denis Mulleman 3, gregoire Cormier 4, fabienne Coury-Lucas 5, Philippe Gaudin 6, Emmanuelle Dernis 7, christine bonnet 8, richard damade 9, jean-luc Grauer 10, Tassadit Ait Abdesselam 11, caroline Karras 12, frederic Liote 13, Pascal Hilliquin 14, antoinette sacchi 15, Jean-Marie Berthelot 16, marc puyraveau 1 and gilles dumoulin 1, 1University Hospital, Besancon, France, 2University Hospital, St Etienne, France, 3University hospital, Tours, France, 4CHD Vendée, La Roche sur Yon, France, 5University Hospital, Lyon, France, 6Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 7Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 8University Hospital, Limoges, France, 9Centre Hospitalier, Chartres, France, 10Centre Hopsitalier, Montelimar, France, 11Centre Hospitalier, Meaux, France, 12Hôpital Saint Joseph, Marseille, France, 13AP-HP, Paris, France, 14Centre Hospitalier, Corbeil Essones, France, 15Centre Hospitalier, Mantes la Jolie, France, 16University Hospital, Nantes, France

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) diseases. Dyslipidemia is a known adverse reaction to tocilizumab (TCZ). TNFa blockade…
  • Abstract Number: 1391 • 2019 ACR/ARP Annual Meeting

    Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study

    Patryk Drobinski1, Anne Bay-Jensen 2, Morten Karsdal 3 and Anne Siebuhr 4, 1University of Copenhagen/Nordic Bioscience, Copenhagen, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Copenhagen, Denmark, 4Nordic Bioscience, Herlev

    Background/Purpose: Response to treatments in Rheumatoid Arthritis (RA) is assessed by symptomatic changes, such as ACR-response and DAS28. However, such assessments do not provide information…
  • Abstract Number: 1397 • 2019 ACR/ARP Annual Meeting

    Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis

    Dimitrios Pappas1, Taylor Blachley 2, Steve Zlotnick 3, Jennie Best 3, Kelechi Emeanuru 2 and Joel Kremer 4, 1Columbia University, New York, NY, 2Corrona, LLC, Waltham, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Clinical studies have demonstrated the efficacy of tocilizumab (TCZ) administered with methotrexate (MTX) in improving rheumatoid arthritis (RA) disease activity in patients who have…
  • Abstract Number: 1405 • 2019 ACR/ARP Annual Meeting

    Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab

    Lovisa Lyngfelt1, Malin Erlandsson 2, Karin Andersson 2, Sofia Silfverswärd 2 and Maria Bokarewa 2, 1Department of Rheumatology and Inflammation Research at Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Adipose tissue is an important player in cardiovascular (CV) morbidity. Thermogenic brown adipocytes, rich with uncoupling protein 1 (UCP1), increase metabolic and CV health.…
  • Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting

    Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

    Maxime Verhoeven1, Janneke Tekstra 1, Attila Pethö-Schramm 2, Michelle Borm 3, Jacob van Laar 1, Floris Lafeber 1, Johannes Bijlsma 1, Johannes Jacobs 1 and Paco Welsing 1, 1UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 2Hoffmann-La Roche, Basel, Basel, Switzerland, 3Roche Nederland BV, Woerden, Netherlands

    Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
  • Abstract Number: 1414 • 2019 ACR/ARP Annual Meeting

    Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab

    Frank Behrens1, Werner A Biewer 2, Gerd Burmester 3, Martin Feuchtenberger 4, Michael W. Hofmann 5, Peter Kästner 6, Herbert Kellner 7, Ramona König 8, Anke Liebhaber 9, Christina Luig 10, Regina Max 11, Patrizia Sternad 12, Hans-Peter Tony 13 and Christopher Amberger 14, 1Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, 2Rheumatologische Schwerpunktpraxis Saarbrücken, Saarbrücken, Germany, 3Charité—University Medicine Berlin, Berlin, Germany, 4Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 5Chugai Pharma Europe Ltd., Frankfurt/Main, Germany, 6MVZ Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, 7Praxis Prof. Herbert Kellner, Munich, Germany, 8Justus-Liebig-Universität Giessen and Kerckhoff-Klinik-Forschungs-GmbH, Giessen, Germany, 9Internistisch-Rheumatologische Arztpraxis, Halle, Halle, Germany, 10Roche Pharma AG, Rheumatologie, Grenzach-Wyhlen, Germany, 11Universitätsklinikum Heidelberg, Heidelberg, Germany, 12Gemeinschaftspraxis, Planegg, Planegg, Germany, 13Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, 14Rheumatologische Gemeinschaftspraxis Dr. Pick/Dr. Amberger, Bad Neuenahr, Germany

    Background/Purpose: In rheumatoid arthritis (RA), the proinflammatory cytokine IL-6 is associated with mental disorders such as depression and anxiety.1 Furthermore, depression and anxiety are comorbidities…
  • Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting

    Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study

    Toshihisa Kojima1, Shuji Asai 1, Masahiro Hanabayashi 2, Masatoshi Hayashi 3, Nobunori Takahashi 1, Yachiyo Kuwatsuka 4, Masahiko Ando 4 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Ichinomiya Municipal Hospital, Ichinomiya, Japan, 3Hayashi Orthopedic Clinic, Nagano, Japan, 4Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…
  • Abstract Number: 1692 • 2019 ACR/ARP Annual Meeting

    Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice

    Iñigo Gonzalez-Mazon1, Lara Sanchez-Bilbao 2, Belén Atienza-Mateo 2, Jose Luis Martín-Varillas 2, DIANA PRIETO- PENA 1, Vanesa Calvo-Río 3, Rosalia Demetrio 4, Natalia Palmou-Fontana 1, Javier Loricera 5, Emma Beltrán Catalán 6, Marisa Hernández Garfella 7, Elia Valls-Pascual 8, Antonio Atanés 9, Miguel Cordero Coma 9, Joan M Nolla 10, Carmen carrasco-Cubero 11, Julio Sánchez 12, Miguel A Gonzalez-Gay 2 and Ricardo Blanco 2, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5H.U. Marques de Valdecilla, Santander, Spain, 6Hospital del Mar, Barcelona, Spain, 7H.G.U. Valencia, Valencia, 8Dr Peset University Hospital, Valencia, Spain, 9HUAC La Coruña, Coruña, Spain, 10Hospital Universitari de Bellvitge, Hospitalet, Spain, 11CHU de Badajoz, Badajoz, Spain, 12Hospital 12 de Octubre, Madrid, Spain

    Background/Purpose: Ocular involvement in Behçet’s disease (BD) is a potential severe and disabling complication. Anti-TNF-α agents have shown an improvement of visual outcome in BD-related…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology